Bronchiolitis obliterans (BO) following allogeneic haematopoietic SCT (HSCT) is a serious complication affecting 1.7-26% of the patients, with a reported mortality rate of 21-100%. It is considered a manifestation of chronic graftversus-host disease, but our knowledge of aetiology and pathogenesis is still limited. Diagnostic criteria are being developed, and will allow more uniform and comparable research activities between centres. At present, no randomised controlled trials have been completed that could demonstrate an effective treatment. Steroids in combination with other immunosuppressive drugs still constitute the backbone of the treatment strategy, and results from our and other centres suggest that monthly infusions of high-dose pulse i.v. methylprednisolone (HDPM) might stabilise the disease and hinder progression. This article provides an overview of the current evidence regarding treatment options for BO and presents the treatment results with HDPM in a paediatric national HSCT-cohort.
Introduction
Bronchiolitis obliterans (BO) is an obstructive lung disease seen after allogeneic haematopoietic SCT (HSCT). 1 Respiratory symptoms include cough, dyspnoea and wheeze, but patients may remain relatively asymptomatic despite moderate-to-severe obstruction. The pronounced variability in reported incidences (1.7-26%) and mortality rates (21-100%) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] of BO may be because of the lack of consistent definitions. [11] [12] [13] [14] [15] [16] No validated treatment protocol has been established.
This article reviews our current knowledge of the pathogenesis of BO and outlines the current practice in the treatment of this serious complication. Finally, we present our experience of high-dose i.v. pulse methylprednisolone treatment (HDPM) in children with BO after allogeneic HSCT.
Pathogenesis
Because BO resembles allograft-rejection in lung-transplant recipients (BO syndrome (BOS)) at a pathological, immunological and physiological level, 17 studies of BO in HSCT patients are discussed along with studies of BOS in lung transplant patients in the following.
Increasing evidence suggests that T-cell-mediated recognition of alloantigens expressed in the lung tissue constitutes a central event in the pathogenesis of BO. Thus, in lung transplanted patients HLA mismatch confers an increased risk, 18 and signs of BO after HSCT is often accompanied by alloreactivity in other organs (for example, skin, liver and eyes). 1, [3] [4] [5] [6] [7] [8] [19] [20] [21] [22] The essential role of T-cellmediated allorecognition was further indicated by a study showing reduced frequency of BO in HSCT patients receiving a T-cell-depleted graft. 23 Other reported risk factors are BU-based conditioning regimens, 9,24-26 the intensity of conditioning, 27 time from leukaemia diagnosis to HSCT, peripheral blood-derived stem cell source, grade II-IV acute GvHD (aGvHD), 9 pre-transplant airflow obstruction and viral respiratory tract infection within the first 100 days after HSCT. 10 The findings are however, not consistent between studies.
Histopathologically, the BO process begins with lymphocyte infiltration around the small vessels and beneath the respiratory epithelial lining in the small airways, followed by epithelial cell necrosis and denudation of mucosa. 28 A secondary cascade of non-specific inflammatory mediators attracts other cells, including neutrophils, and leads to migration of fibroblasts, proliferation of smooth muscle cells, and eventually collagen deposition and fibrous obliteration of the lumen. 29, 30 Interestingly, studies of BOS in lung transplant recipients have suggested a central role of T-cell-mediated reactivity towards collagen. Thus, infiltrating monocytes as well as collagen type V (col(V))-specific Th17 cells are seen in the inflammatory focus. 31 Col(V), which is essential for lungtissue elasticity and compliance, is in healthy individuals not exposed to immune cells. It is conceivable, although not yet shown, that T-cell-mediated recognition of col(V) may also play a pathogenetic role in BO after HSCT, where col(V) may be exposed as a result of epithelial damage by chemotherapy and/or irradiation.
T-cell activation is initiated by APCs-usually DCs and differentiation of T-cells into T helper 1 (Th1), Th2, Th17 and/or regulatory T-cells (T reg ) is determined by the cytokine profiles in the microenvironment during T-cell differentiation. 32 Animal studies have suggested a mutually exclusive differentiation of CD4 þ cells into either Th17 or T reg , depending on the presence (Th17) or absence (T reg ) of IL-6. 33 The Th17 subset is important in the development of inflammation and autoimmunity, while T regs may downregulate inflammatory activity in autoimmune diseases and inhibit graft rejection in organ transplantation. 32 Lung transplant patients affected with BOS have a lower level of circulating CD4 þ CD25 þ T reg than patients in a stable clinical condition. 34 In line with this, an animal model of BOS has shown increased local IL-17 production, with decreased peripheral blood levels of T regs . 35 IL-17 has been shown to induce IL-8 secretion, 36, 37 which in turn is related to airway neutrophilia. 38, 39 This may be of potential clinical interest because the number of neutrophils in the airways has been associated with clinically defined BOS phenotypes following lung transplantation. 40 Increasing interest is rewarded the role of B cells in chronic GvHD. 41 Elevated blood levels of B-cell activating factor, essential for survival and differentiation of B cells, have been demonstrated in cGvHD- 42, 43 and BO-patients. 44 A study in lung transplant recipients has suggested a temporal relationship between development of anti-HLA antibodies and BOS. 45 Murine studies have demonstrated that specific antibodies towards HLA class I activate parenchymal cells in a tracheal allograft, resulting in proliferation, growth factor production and apoptosis. This process leads to the activation of fibroblasts, tissue remodelling and proliferation of fibrous tissue observed during BOS development. 46 Taken together, these data suggest a model in which respiratory insults and extensive inflammation during the transplantation constitute a 'primary hit' that results in upregulation of MHC molecules and exposure of 'neoantigens' including col(V). This leads to Th17-biased differentiation of T-cells, and subsequently IL-8-driven neutrophilia. B-cell activation, Ag presentation and production of anti-HLA Abs may result in aggravation and maintenance of the inflammatory response and ultimately epithelial destruction and pulmonary fibrosis.
Efforts to prevent and treat BO have been directed towards various steps of this cascade, but the limited clinical success underlines that our knowledge of this condition is still sparse.
Diagnosis
Early diagnosis of BO is difficult, because patients are often asymptomatic in the early stages of the disease 7 Chronic GvHD may be diagnosed when BO is proven by lung biopsy. BO diagnosed via clinical criteria requires at least one manifestation in a separate organ system to establish the diagnosis of cGvHD. 12 The term idiopatic pneumonia syndrome is by the American Thoracic Society defined as widespread alveloar injury evidenced by radiology, signs and symptoms of pneumonia and either an increased alveolar to arterial oxygen gradient or a restrictive pulmonary function test not attributed to infection, cardiac dysfunction, renal failure or iatrogenic fluid overload. 47 Although BO primarily is defined as an obstructive lung disease, cases of BO will often also fit the idiopatic pneumonia syndrome definition. Most cases of idiopatic pneumonia syndrome, however, occurs in the first 3 months after SCT. [47] [48] [49] [50] The need for further development of these criteria is, however, a matter of ongoing discussion. In a retrospective study by Williams et al., 11 only 18% of previously diagnosed BO patients with a FEV 1 of o55%, met the NIH consensus criteria. As forced vital capacity and total lung capacity in HSCT patients can be falsely low because of restriction from scleroderma or myositis, these authors suggested a definition of obstruction confirmed by either FEV 1 /slow vital capacity or air trapping on high-resolution computed tomography with residual volume or residual volume/total lung capacity4120%.
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Treatment
Although a number of first-or second-line treatment strategies have been described in the literature, no randomised controlled trials have described a long lasting effect of any treatment modality for BO. [51] [52] [53] A Medline search on English literature, including prospective and retrospective studies, randomised or not randomised, with more than three participants published since 2000, revealed 18 studies 54-72 and 10 treatment modalities (Table 1) . Using the NIH grading system, no treatment modality reached an evidence level above III (evidence from opinions of respected authorities based on clinical experience, descriptive studies or reports from expert committees). The strength of recommendation was C (insufficient evidence to support recommendation or outweigh adverse effects or Median age all patients 29 years (range 10-62) Complete remission after 6 months in 3/11.
Partial remission in 4/11 (sustained improvement in PFT or ability to taper corticosteroids by at least 50% without deterioration). 9/11 alive at follow-up.
Median follow-up 17 months (range 8-22)
Bronchiolitis obliterans in clinical practice HH Uhlving et al costs of the approach) for all treatment modalities apart from treatment with corticosteroids (A-III), which is discussed in the following.
Corticosteroids
In 2005, Ratjen et al. 54 reported their experience with HDPM treatment in a small cohort of nine children. To our knowledge, no other published study has described this treatment regimen for BO after HSCT. HDPM treatment is recommended in other inflammatory lung diseases in children. 75, 76 Reported side effects include transient flushing, headache, mood changes 77 and sinus bradycardia, 78 but no serious long-term events have been described in children. HDPM has been the standard treatment of BO since 1999 at our centre, and we here summarise the results.
HDPM treatment in the Danish paediatric BO cohort. Within the recent 12 years BO has been diagnosed in 13 children following HSCT (median age 9.3 years, range 0.6-13.4) at the national paediatric HSCT centre in Denmark. This corresponds to 7.3% of Danish SCT patients below 16 years of age in this period. Nine of the patients were able to perform a reliable spirometry and had significantly reduced levels of function (Table 2 ). In five cases BO was confirmed by open lung biopsy. The final diagnosis of BO was based on a combination of decreased lung function parameters, highresolution computed tomography findings, lung biopsy and/or clinical symptoms, but none of the nine patients fully met the NIH clinical criteria for BO. Our patient cohort was treated with a combination of conventional immunosuppressive agents (Table 3 ) and i.v. HDPM 15 mg/kg for 2-3 consecutive days every 4-6 weeks. Median time from HSCT to first BO symptoms was 141 days (range 53-254) and from symptoms to first course of HDPM 35 days (3-244). Spirometry was performed before HSCT, before initiating HDPM therapy, and then monthly. Patients with FEV 1 o35% and patients who were unable to taper oral prednisolone within 6 months of HDPM initiation were given additional treatment with monthly infusions of infliximab.
One patient (no. 8) died of respiratory insufficiency because of CMV-pneumonia 1 month after initiation of therapy, whereas one patient (no. 6) died of leukaemic relapse. In the patients tested, a significant increase in FEV 1 was seen 3 months (P ¼ 0.010) and 1 year (P ¼ 0.011) after initiation of HDPM (the Wilcoxon rank sum test), with median increase in FEV 1 from 48.1% at treatment initiation to 71.4% and 83.0%, respectively (Figure 1) . During further follow-up lung function generally stabilised at a moderately reduced level.
This small population-based study of a rather heterogeneous group of patients has obvious limitations, shared by the majority of the previous studies presented in Table 1 , and does not allow firm conclusions. Our data suggests that stabilisation of lung function in BO patients may be achieved by early commencement on high-dose pulse corticosteroids in combination with other immunosuppressive treatment. The effect of HDPM on relapse rate and infectious complications cannot be properly assessed in a study of this size. Further studies, preferebly a multicenter randomised study would be needed to properly adress both treatment response and possible adverse effects of HDPM therapy.
Corticosteroids have been the backbone of cGvHD therapy, since Sullivan et al.
14 in 1981 demonstrated improved outcome in cGvHD patients receiving corticosteroids in combination with other immunosuppressors. 14 The role of prednisolone was further established in two randomised studies, 79, 80 where the addition of azathioprine 79 and cyclosporine 80 did not seem to further improve outcome in standard risk cGvHD patients. However, the effect of orally administrated prednisolone on lung involvement was not reported in those studies. First-line treatment of cGVHD mainly consists of prednisolone with a starting dose of 1 mg/kg/day orally. 52 Inhaled corticosteroids in combination with long-acting bronchodilators are now being tested in BO patients in a prospective multicentre, randomised double-blinded trial. 81 A pilot study of 13 patients with respiratory symptoms, but no extrapulmonary signs of cGvHD, showed some effect on lung function parameters 55 (Table 1) .
TNF-a inhibitors
Insights into the role of proinflammatory cytokines in disease pathogenesis, has led to the use of TNF-a inhibitors as second-line BO treatment. The three patients in the Danish cohort, who received infliximab due to a decrease in lung function during the standard HDPM regimen, experienced stabilisation after commencement of infliximab. A case study from Texas described complete resolution of symptoms in a patient with steroid refractory BO on etanercept treatment. 82 The two studies on the effect of infliximab described in Table 1 (refs 59,60) suggests some improvement. An ongoing study of etanercept therapy at the Ann Arbor Cancer Center (NCT00141726) may provide further insights.
Azithromycin
The ability of azithromycin to inhibit airway neutrophilia and IL-8 production 39, 40 may explain the improvement after treatment in a subgroup of lung transplant recipients with BOS. 83, 84 Similar positive results have been reported in a preliminary study on 8 patients with BO after HSCT 57 (Table 1) . However, a randomised placebo-controlled clinical trial from Hong Kong 58 failed to prove superiority of azithromycin to placebo when initiated (mean) 4.3 and 5.8 years, respectively, after BO diagnosis. A recently published case-series indicates a steroid sparing effect of azithromycin in combination with inhaled corticosteroids and montelukast in patients with newly diagnosed BO. 85 Further studies are needed to establish an eventual effect of azythromycin on incipient BO.
Extracorporeal photopheresis
Selective downregulation of T-cell-mediated immunity is thought to explain the effect of extracorporeal photopheresis in the treatment of GvHD. 86 Though several studies have been performed in patients with BO after HSCT [61] [62] [63] [64] [65] [87] [88] [89] [90] [91] and lung transplantation, [92] [93] [94] the studies are difficult to interpret because of the heterogeneity in the treatment schedules, diagnostic criteria and response assessment criteria (Table 1) . A prospective randomised study of extracorporeal photopheresis treatment performed by Flowers et al. 61 revealed a significant improvement of cGVHD in the skin, and indicated a steroid sparing effect on cGvHD in general. No effect on lung function parameters was noted.
Rituximab
An attempt to attack the B-cell response suspected to be a part of cGvHD aetiology has led to the application of the monoclonal CD20-Ab Rituximab. Although several studies have suggested an effect on cGvHD in the skin, 66, [95] [96] [97] [98] no convincing effect on BO has been established. 66, 67 
Conclusion
Solid evidence regarding the efficacy of the various available treatment modalities in BO is still sparse. Ongoing clinical trials together with new insights into the pathogenesis will hopefully contribute to fill this gap. Though established clinical criteria are important as a research tool, the experience with the NIH Consensus Criteria may indicate a need for further development of clinical criteria and simplification of these. Our experience emphasises the need for improved diagnostic criteria, in particular for the young children who are unable to perform spirometry.
The preliminary experiences with HDPM treatment from our and other centres suggest that the efficacy of this treatment regimen, including the long-term effects deserves further validation in clinical trials. Though alternative treatment options may seem promising, corticosteroids are still likely to remain a mainstay in GvHD treatment in the coming years. However, with improved insights into the pathogenesis of BO new treatment modalities, including cytokine antagonists and cellular therapy, may change treatment strategies fundamentally.
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